Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dexamethasone sodium phosphate Visulex - Aciont

Next Previous
Drug Profile

Dexamethasone sodium phosphate Visulex - Aciont

Alternative Names: Dexamethasone sodium phosphate - Visulex®; DSP-Visulex®

Latest Information Update: 14 Jan 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Aciont
  • Class Anti-inflammatories; Antiallergics; Antiemetics; Antihyperglycaemics; Antineoplastics; Antirheumatics; Eye disorder therapies; Fluorinated steroids; Glucocorticoids; Ketones; Non-opioid analgesics; Pregnadienetriols; Small molecules; Vestibular disorder therapies
  • Mechanism of Action Glucocorticoid receptor agonists; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Uveitis

Most Recent Events

  • 11 Oct 2019 Aciont has patent protection for Visulex ocular drug delivery system in USA
  • 05 Apr 2017 Phase-I/II development for Uveitis is ongoing in USA (Ophthalmic,Controlled release) (NCT02309385)
  • 03 Mar 2017 Aciont completes a phase I/II trial for Uveitis in USA (Ophthalmic, Controlled release) (NCT02309385)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top